Vericel VCEL Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product sales, net by Product | ||||||
| Biopsy kits | $2.62M+0.4% | $2.61M+6.1% | $2.46M+8.1% | $2.27M+7.1% | $2.12M+1.5% | |
| Epicel | $37.99M+18.5% | $32.07M+7.0% | $29.97M-5.7% | $31.78M+2.8% | $30.92M-15.6% | |
| M A C I Implants and kits | $249.61M+4.2% | $239.51M+7.0% | $223.75M+5.2% | $212.75M+4.6% | $203.42M+3.1% | |
| MACI implants, kits, and instruments | $189.18M+5.4% | $179.5M+9.5% | $163.92M+6.1% | $154.46M+6.0% | $145.74M+3.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vericel break its business down?
- Vericel (VCEL) reports product sales, net by product across 4 parts — Biopsy kits, Epicel, M A C I Implants and kits and MACI implants, kits, and instruments. Each is extracted from the segment footnotes and tracked over time.
- Where does Vericel's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vericel's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
